In-vitro synergy of paromomycin with metronidazole alone or metronidazole plus hydroxymetronidazole against Helicobacter pylori

The in-vitro activities of paromomycin and metronidazole alone or paromomycin and metronidazole plus hydroxymetronidazole (2:1 ratio) were studied against 19 Helicobacter pylori isolates using an in-vitro chequerboard technique. Partial synergy was demonstrated for the majority of isolates (11/19) f...

Full description

Saved in:
Bibliographic Details
Published inJournal of antimicrobial chemotherapy Vol. 43; no. 3; pp. 403 - 406
Main Authors MEYER, J. M, SEONYOUNG RYU, PENDLAND, S. L, KANYOK, T. P, DANZIGER, L. H
Format Journal Article
LanguageEnglish
Published Oxford Oxford University Press 01.03.1999
Subjects
Anti-Bacterial Agents - pharmacology
Antibacterial agents
Antibiotics. Antiinfectious agents. Antiparasitic agents
Biological and medical sciences
Drug Combinations
Drug Synergism
Helicobacter pylori - drug effects
Medical sciences
Metronidazole - pharmacology
Microbial Sensitivity Tests
Paromomycin - pharmacology
Pharmacology. Drug treatments
Nitro compound
Imidazole derivatives
Drug combination
Spirillales
Spirillaceae
In vitro
Biological activity
Antiprotozoal agent
Antibiotic
Sensitivity resistance
Helicobacter pylori
Aminoglycoside
Parasiticid
Bacteria
Metronidazole
Antibacterial agent
Clinical isolate
Paromomycin
Online AccessGet full text

Cover

More Information
Summary:The in-vitro activities of paromomycin and metronidazole alone or paromomycin and metronidazole plus hydroxymetronidazole (2:1 ratio) were studied against 19 Helicobacter pylori isolates using an in-vitro chequerboard technique. Partial synergy was demonstrated for the majority of isolates (11/19) for both combinations tested. When hydroxymetronidazole was added to the parent compound, the number of metronidazole-sensitive isolates demonstrating synergy increased to 5/12, compared with 1/12 for the combination that did not include the metabolite. In metronidazole-resistant isolates there was a shift from an additive effect to partial synergy for the combination containing hydroxymetronidazole. The in-vitro activity of paromomycin and the synergic effect that is achieved in combination with metronidazole and hydroxymetronidazole render paromomycin suitable for further investigation as a treatment option for H. pylori infection.
ISSN:0305-7453
1460-2091
1460-2091
DOI:10.1093/jac/43.3.403